News Headlines Article

Amgen to pay $71 million to settle claims of off-label drug uses
Los Angeles Business Journal

Biotechnology company Amgen Inc. has agreed to pay $71 million to 48 states and the District of Columbia to settle claims that it improperly promoted its top-selling drugs, Aranesp and Enbrel, for uses not approved by the Food and Drug Administration. California will receive $4.6 million from the settlement, Attorney General Kamala Harris announced Tuesday.